Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORCINCH-HF
NCT04331769Suspended
- Sponsor
- Ancora Heart
- Start
- Dec 2020
- Primary completion
- Dec 2026
- Countries
- 10
01
Overview
Randomised, open-label trial in heart failure with reduced ejection fraction (HFrEF) and dilated cardiomyopathy (DCM) (2 arms), sponsored by Ancora Heart. Primary endpoints: Freedom from device- or femoral artery access-related major adverse events at 365 days, Kansas City Cardiomyopathy Questionnaire Quality of Life Questionnaire Score at 180 days and 2 more. Started Dec 2020; status: suspended.
02
Conditions
heart failure with reduced ejection fraction (HFrEF)dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT04331769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04331769.